Evidence map›Paper›PMID 32797239›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?

Christopher Cerda-Contreras, Laura Nuzzolo-Shihadeh, Adrián Camacho-Ortiz, Eduardo Perez-Alba

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. COVID-19 and the Pancreas: A Narrative Review.Life (Basel, Switzerland) · 2022
    Review
  3. Review
  4. Coronavirus disease 2019 and the pancreas.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christopher Cerda-ContrerasServicio de Medicina Interna, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.
Laura Nuzzolo-ShihadehServicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.
Adrián Camacho-OrtizServicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.ORCID 0000-0002-8044-0094
Eduardo Perez-AlbaServicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.ORCID 0000-0002-6642-2770
Universidad Autónoma de Nuevo León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAzetidinesHumansPancreasPurinesPyrazolesSARS-CoV-2SulfonamidesAzetidinesbaricitinibPurinesPyrazolesSulfonamides

Identifiers

PMID32797239
PMCPMC7454364
OpenAlexW3048808767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.